Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
The effects of treatments to programmed death ligand-1 (PD-L1) expression is unknown. The aim of this study was to investigate the impact of neoadjuvant chemotherapy (NACT) on PD-L1 expression in non-small cell lung cancer (NSCLC) patients. PD-L1 expression was detected by immunohistochemistry (IHC)...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2016-01, Vol.6 (1), p.20090-20090, Article 20090 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 20090 |
|---|---|
| container_issue | 1 |
| container_start_page | 20090 |
| container_title | Scientific reports |
| container_volume | 6 |
| creator | Sheng, Jin Fang, Wenfeng Yu, Juan Chen, Nan Zhan, Jianhua Ma, Yuxiang Yang, Yunpeng Huang, Yan Zhao, Hongyun Zhang, Li |
| description | The effects of treatments to programmed death ligand-1 (PD-L1) expression is unknown. The aim of this study was to investigate the impact of neoadjuvant chemotherapy (NACT) on PD-L1 expression in non-small cell lung cancer (NSCLC) patients. PD-L1 expression was detected by immunohistochemistry (IHC) method in 32 paired tumor specimens pre and post-NACT. The positivity of PD-L1 on tumor cells (TCs) changed from 75% to 37.5% after NACT (
p
= 0.003). Cases with IHC score of 1, 2, 3 all underwent apparent decrease (p = 0.007). However, no significant changes were observed on tumour-infiltrating immune cells (ICs) (p = 0.337). Subgroup and semiquantitative analyses all presented similar results. Moreover, patients with response to NACT presented significantly reduced PD-L1 expression on TCs (p = 0.004). Although it was not confirmed by the Cox proportional hazard regression model, there was an apparent difference in disease-free-survival (DFS) between negative-to-positive switch of PD-L1 status and the contrary group (median DFS: 9.6 versus 25.9,
p
= 0.005). Our data revealed that antecedent chemotherapy for NSCLC may results in inconsistency of PD-L1 expression. PD-L1 expression is suggested to be monitored around treatment and on serial samples, at least, on the latest tumor specimen. |
| doi_str_mv | 10.1038/srep20090 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4731819</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1899046940</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-103446901f17ee4c15c49ae8facb0179488763a265ecb2b6f6fdaf0c1f06eb903</originalsourceid><addsrcrecordid>eNplkV9r2zAUxUXZaELXh36BIdjLOnArybJsvQxK6f5AoC_ts5CVK8fBljzJDs23r7KkIVv1IsH56dx7OAhdUXJDSV7dxgADI0SSMzRnhBcZyxn7cPKeocsY1ySdgklO5TmaMVExlpdyjqaHlyFAjK132Fs8BN8E3fewxEvQ4wp3baPdMqM46ePU-4ANdF3EGx1aiIkHnHQ8-Dhis4LejysIetji1mHnXRZ73XV__-Bucg022hkIn9BHq7sIl4f7Aj3_eHi6_5UtHn_-vr9bZKYgfMxSPs6FJNTSEoAbWhguNVRWm5rQUvKqKkWumSjA1KwWVtiltsRQSwTUkuQX6Pved5jqlMmAG4Pu1BDaXoet8rpV_yquXanGbxQvc1pRmQy-HgyC_zNBHFXfxl0a7cBPUdFSUC6KStCEfvkPXfspuBRP0UpKkoLw3UbXe8oEH1N19rgMJWrXpzr2mdjPp9sfybf2EvBtD8QkuQbCych3bq807atC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1899046940</pqid></control><display><type>article</type><title>Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer</title><source>MEDLINE</source><source>Nature Free</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature OA Free Journals</source><creator>Sheng, Jin ; Fang, Wenfeng ; Yu, Juan ; Chen, Nan ; Zhan, Jianhua ; Ma, Yuxiang ; Yang, Yunpeng ; Huang, Yan ; Zhao, Hongyun ; Zhang, Li</creator><creatorcontrib>Sheng, Jin ; Fang, Wenfeng ; Yu, Juan ; Chen, Nan ; Zhan, Jianhua ; Ma, Yuxiang ; Yang, Yunpeng ; Huang, Yan ; Zhao, Hongyun ; Zhang, Li</creatorcontrib><description>The effects of treatments to programmed death ligand-1 (PD-L1) expression is unknown. The aim of this study was to investigate the impact of neoadjuvant chemotherapy (NACT) on PD-L1 expression in non-small cell lung cancer (NSCLC) patients. PD-L1 expression was detected by immunohistochemistry (IHC) method in 32 paired tumor specimens pre and post-NACT. The positivity of PD-L1 on tumor cells (TCs) changed from 75% to 37.5% after NACT (
p
= 0.003). Cases with IHC score of 1, 2, 3 all underwent apparent decrease (p = 0.007). However, no significant changes were observed on tumour-infiltrating immune cells (ICs) (p = 0.337). Subgroup and semiquantitative analyses all presented similar results. Moreover, patients with response to NACT presented significantly reduced PD-L1 expression on TCs (p = 0.004). Although it was not confirmed by the Cox proportional hazard regression model, there was an apparent difference in disease-free-survival (DFS) between negative-to-positive switch of PD-L1 status and the contrary group (median DFS: 9.6 versus 25.9,
p
= 0.005). Our data revealed that antecedent chemotherapy for NSCLC may results in inconsistency of PD-L1 expression. PD-L1 expression is suggested to be monitored around treatment and on serial samples, at least, on the latest tumor specimen.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/srep20090</identifier><identifier>PMID: 26822379</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1612/1350 ; 692/4028/67/1612/1350 ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Apoptosis ; B7-H1 Antigen - genetics ; B7-H1 Antigen - metabolism ; Biomarkers, Tumor ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - metabolism ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Chemotherapy ; Female ; Gene Expression Regulation ; Humanities and Social Sciences ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Ligands ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - metabolism ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Middle Aged ; multidisciplinary ; Mutation ; Neoplasm Staging ; Non-small cell lung carcinoma ; PD-L1 protein ; Prognosis ; Science ; Treatment Outcome ; Tumor cells ; Tumors</subject><ispartof>Scientific reports, 2016-01, Vol.6 (1), p.20090-20090, Article 20090</ispartof><rights>The Author(s) 2016</rights><rights>Copyright Nature Publishing Group Jan 2016</rights><rights>Copyright © 2016, Macmillan Publishers Limited 2016 Macmillan Publishers Limited</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-103446901f17ee4c15c49ae8facb0179488763a265ecb2b6f6fdaf0c1f06eb903</citedby><cites>FETCH-LOGICAL-c504t-103446901f17ee4c15c49ae8facb0179488763a265ecb2b6f6fdaf0c1f06eb903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731819/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731819/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26822379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sheng, Jin</creatorcontrib><creatorcontrib>Fang, Wenfeng</creatorcontrib><creatorcontrib>Yu, Juan</creatorcontrib><creatorcontrib>Chen, Nan</creatorcontrib><creatorcontrib>Zhan, Jianhua</creatorcontrib><creatorcontrib>Ma, Yuxiang</creatorcontrib><creatorcontrib>Yang, Yunpeng</creatorcontrib><creatorcontrib>Huang, Yan</creatorcontrib><creatorcontrib>Zhao, Hongyun</creatorcontrib><creatorcontrib>Zhang, Li</creatorcontrib><title>Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>The effects of treatments to programmed death ligand-1 (PD-L1) expression is unknown. The aim of this study was to investigate the impact of neoadjuvant chemotherapy (NACT) on PD-L1 expression in non-small cell lung cancer (NSCLC) patients. PD-L1 expression was detected by immunohistochemistry (IHC) method in 32 paired tumor specimens pre and post-NACT. The positivity of PD-L1 on tumor cells (TCs) changed from 75% to 37.5% after NACT (
p
= 0.003). Cases with IHC score of 1, 2, 3 all underwent apparent decrease (p = 0.007). However, no significant changes were observed on tumour-infiltrating immune cells (ICs) (p = 0.337). Subgroup and semiquantitative analyses all presented similar results. Moreover, patients with response to NACT presented significantly reduced PD-L1 expression on TCs (p = 0.004). Although it was not confirmed by the Cox proportional hazard regression model, there was an apparent difference in disease-free-survival (DFS) between negative-to-positive switch of PD-L1 status and the contrary group (median DFS: 9.6 versus 25.9,
p
= 0.005). Our data revealed that antecedent chemotherapy for NSCLC may results in inconsistency of PD-L1 expression. PD-L1 expression is suggested to be monitored around treatment and on serial samples, at least, on the latest tumor specimen.</description><subject>631/67/1612/1350</subject><subject>692/4028/67/1612/1350</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Apoptosis</subject><subject>B7-H1 Antigen - genetics</subject><subject>B7-H1 Antigen - metabolism</subject><subject>Biomarkers, Tumor</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Gene Expression Regulation</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kaplan-Meier Estimate</subject><subject>Ligands</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Mutation</subject><subject>Neoplasm Staging</subject><subject>Non-small cell lung carcinoma</subject><subject>PD-L1 protein</subject><subject>Prognosis</subject><subject>Science</subject><subject>Treatment Outcome</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNplkV9r2zAUxUXZaELXh36BIdjLOnArybJsvQxK6f5AoC_ts5CVK8fBljzJDs23r7KkIVv1IsH56dx7OAhdUXJDSV7dxgADI0SSMzRnhBcZyxn7cPKeocsY1ySdgklO5TmaMVExlpdyjqaHlyFAjK132Fs8BN8E3fewxEvQ4wp3baPdMqM46ePU-4ANdF3EGx1aiIkHnHQ8-Dhis4LejysIetji1mHnXRZ73XV__-Bucg022hkIn9BHq7sIl4f7Aj3_eHi6_5UtHn_-vr9bZKYgfMxSPs6FJNTSEoAbWhguNVRWm5rQUvKqKkWumSjA1KwWVtiltsRQSwTUkuQX6Pved5jqlMmAG4Pu1BDaXoet8rpV_yquXanGbxQvc1pRmQy-HgyC_zNBHFXfxl0a7cBPUdFSUC6KStCEfvkPXfspuBRP0UpKkoLw3UbXe8oEH1N19rgMJWrXpzr2mdjPp9sfybf2EvBtD8QkuQbCych3bq807atC</recordid><startdate>20160129</startdate><enddate>20160129</enddate><creator>Sheng, Jin</creator><creator>Fang, Wenfeng</creator><creator>Yu, Juan</creator><creator>Chen, Nan</creator><creator>Zhan, Jianhua</creator><creator>Ma, Yuxiang</creator><creator>Yang, Yunpeng</creator><creator>Huang, Yan</creator><creator>Zhao, Hongyun</creator><creator>Zhang, Li</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160129</creationdate><title>Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer</title><author>Sheng, Jin ; Fang, Wenfeng ; Yu, Juan ; Chen, Nan ; Zhan, Jianhua ; Ma, Yuxiang ; Yang, Yunpeng ; Huang, Yan ; Zhao, Hongyun ; Zhang, Li</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-103446901f17ee4c15c49ae8facb0179488763a265ecb2b6f6fdaf0c1f06eb903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>631/67/1612/1350</topic><topic>692/4028/67/1612/1350</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Apoptosis</topic><topic>B7-H1 Antigen - genetics</topic><topic>B7-H1 Antigen - metabolism</topic><topic>Biomarkers, Tumor</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Gene Expression Regulation</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kaplan-Meier Estimate</topic><topic>Ligands</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Mutation</topic><topic>Neoplasm Staging</topic><topic>Non-small cell lung carcinoma</topic><topic>PD-L1 protein</topic><topic>Prognosis</topic><topic>Science</topic><topic>Treatment Outcome</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sheng, Jin</creatorcontrib><creatorcontrib>Fang, Wenfeng</creatorcontrib><creatorcontrib>Yu, Juan</creatorcontrib><creatorcontrib>Chen, Nan</creatorcontrib><creatorcontrib>Zhan, Jianhua</creatorcontrib><creatorcontrib>Ma, Yuxiang</creatorcontrib><creatorcontrib>Yang, Yunpeng</creatorcontrib><creatorcontrib>Huang, Yan</creatorcontrib><creatorcontrib>Zhao, Hongyun</creatorcontrib><creatorcontrib>Zhang, Li</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sheng, Jin</au><au>Fang, Wenfeng</au><au>Yu, Juan</au><au>Chen, Nan</au><au>Zhan, Jianhua</au><au>Ma, Yuxiang</au><au>Yang, Yunpeng</au><au>Huang, Yan</au><au>Zhao, Hongyun</au><au>Zhang, Li</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2016-01-29</date><risdate>2016</risdate><volume>6</volume><issue>1</issue><spage>20090</spage><epage>20090</epage><pages>20090-20090</pages><artnum>20090</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>The effects of treatments to programmed death ligand-1 (PD-L1) expression is unknown. The aim of this study was to investigate the impact of neoadjuvant chemotherapy (NACT) on PD-L1 expression in non-small cell lung cancer (NSCLC) patients. PD-L1 expression was detected by immunohistochemistry (IHC) method in 32 paired tumor specimens pre and post-NACT. The positivity of PD-L1 on tumor cells (TCs) changed from 75% to 37.5% after NACT (
p
= 0.003). Cases with IHC score of 1, 2, 3 all underwent apparent decrease (p = 0.007). However, no significant changes were observed on tumour-infiltrating immune cells (ICs) (p = 0.337). Subgroup and semiquantitative analyses all presented similar results. Moreover, patients with response to NACT presented significantly reduced PD-L1 expression on TCs (p = 0.004). Although it was not confirmed by the Cox proportional hazard regression model, there was an apparent difference in disease-free-survival (DFS) between negative-to-positive switch of PD-L1 status and the contrary group (median DFS: 9.6 versus 25.9,
p
= 0.005). Our data revealed that antecedent chemotherapy for NSCLC may results in inconsistency of PD-L1 expression. PD-L1 expression is suggested to be monitored around treatment and on serial samples, at least, on the latest tumor specimen.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>26822379</pmid><doi>10.1038/srep20090</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2016-01, Vol.6 (1), p.20090-20090, Article 20090 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4731819 |
| source | MEDLINE; Nature Free; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry; Springer Nature OA Free Journals |
| subjects | 631/67/1612/1350 692/4028/67/1612/1350 Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis B7-H1 Antigen - genetics B7-H1 Antigen - metabolism Biomarkers, Tumor Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Female Gene Expression Regulation Humanities and Social Sciences Humans Immunohistochemistry Kaplan-Meier Estimate Ligands Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged multidisciplinary Mutation Neoplasm Staging Non-small cell lung carcinoma PD-L1 protein Prognosis Science Treatment Outcome Tumor cells Tumors |
| title | Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T15%3A09%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20programmed%20death%20ligand-1%20on%20tumor%20cells%20varies%20pre%20and%20post%20chemotherapy%20in%20non-small%20cell%20lung%20cancer&rft.jtitle=Scientific%20reports&rft.au=Sheng,%20Jin&rft.date=2016-01-29&rft.volume=6&rft.issue=1&rft.spage=20090&rft.epage=20090&rft.pages=20090-20090&rft.artnum=20090&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/srep20090&rft_dat=%3Cproquest_pubme%3E1899046940%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1899046940&rft_id=info:pmid/26822379&rfr_iscdi=true |